Back to search

Article

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study

2023-11-20

Abstract excerpt

<title>Abstract</title> <p>The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome after bridging with radiotherapy (RT) and other bridging strategies. Among 148 patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
78ed5dcf-815e-58d9-bb91-3acbf21764eb
DOI
10.21203/rs.3.rs-3573162/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter studyDOI 10.21203/rs.3.rs-3573162/v1
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasSemantic proximity
Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity
Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity
A CAR-T response prediction model for r/r B-NHL patients based on a T-cell subset nomogramSemantic proximity
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity
Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Semantic proximity
Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimensSemantic proximity
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphomaSemantic proximity
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Semantic proximity
Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA programSemantic proximity
One Patient Diagnosed With Primary Refractory Diffuse Large B Cell Lymphoma Successfully Salvaged With BCL2 Inhibitor Followed by anti-CD19 CAR-T Suffered From a Secondary Onset of Severely CRSSemantic proximity
BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation FeasibilitySemantic proximity
Select a neighboring publication to make it the new centre.